Core Insights - Revenue growth was primarily driven by a 29% year-over-year increase in commercial cell and gene therapy support, which now represents 20% of total revenue [1] - The company maintains a dominant market position, supporting approximately 70% of all cell and gene therapy industry clinical trials [1] - Management describes the clinical pipeline as 'spring-loaded' for future commercial revenue, with 86 trials in Phase III and 361 in Phase II [1] Financial Performance - Operational discipline and cost reduction initiatives resulted in a $12 million year-over-year improvement in adjusted EBITDA and a 47% gross margin [1] Strategic Initiatives - The strategic sale of CRYOPDP to DHL provided a substantial capital infusion and established a partnership to leverage DHL's global scale in APAC and EMEA regions [1] - Strategic collaborations with Cardinal Health and Parexel aim to standardize supply chain solutions and embed Cryoport deeper into the life sciences ecosystem [1] - Internal investments focused on expanding global infrastructure, including new supply chain centers in Paris and California to support commercial client scaling [1]